{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:56:03Z","timestamp":1790222163901,"version":"4.1.0"},"reference-count":93,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Incyte, AstraZeneca, Lilly Oncology"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.2217\/fon.14.272","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T10:06:06Z","timestamp":1426068366000},"page":"719-733","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":71,"title":["Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis"],"prefix":"10.1080","volume":"11","author":[{"given":"Cecilia","family":"Arana Yi","sequence":"first","affiliation":[{"name":"University of New Mexico Cancer Center,\r1201 Camino de Salud NE,\rAlbuquerque,\rNM 87131,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S","family":"Tam","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology,Peter MacCallum Cancer Centre,St Andrew\u2019s Place,East Melbourne,\rVictoria,\rAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia,MD Anderson Cancer Center,\r1515 Holcombe Blvd Suite, 428,\rHouston,\rTX 77030,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,3,11]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.019"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23384"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23417"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"issue":"9","key":"e_1_3_2_9_1","first-page":"1","article-title":"Clinical and laboratory features of myelofibrosis and limitations of current therapies","volume":"9","author":"Gregory SA","year":"2011","unstructured":"Gregory SA , MesaRA, HoffmanR, ShammoJM. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin. Adv. Hematol. Oncol.9(9 Suppl. 22), 1\u201316 (2011).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.035"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.04.017"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0869-8"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28857"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.87"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.769537"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.76"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-530865"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554634"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3264"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.19.13480"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.3"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.119"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537167"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.57"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-399048"},{"key":"e_1_3_2_34_1","unstructured":"Incyte Corporation\n. Jakafi (ruxolitinib) tablets [prescribing information] (2014). www.incyte.com\/products\/uspi_jakafi.pdf."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.393.393"},{"key":"e_1_3_2_38_1","unstructured":"Sanofi discontinues clinical development of investigational JAK2 agent fedratinib (SAR302503). Press release. http:\/\/m-en.sanofi.com\/Images\/34935_20131118_JAK-2-FEDRATINIB_en.pdf."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058883"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.12.006"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.061390"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12459"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-320069"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.06.012"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010389469"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.102"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011405663"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.77"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-446849"},{"issue":"21","key":"e_1_3_2_51_1","article-title":"Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy","volume":"122","author":"Kvasnicka HM","year":"2013","unstructured":"Kvasnicka HM , ThieleJ, Bueso-RamosCEet al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood122(21), Abstract 4055 (2013).","journal-title":"Blood"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095109"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2096-y"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12274"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4489"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.279.279"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12375"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.092155"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536557"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1400499"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.1733.1733"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.083543"},{"issue":"21","key":"e_1_3_2_65_1","first-page":"2820","article-title":"A pooled overall survival analysis of the COMFORT Studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis","volume":"122","author":"Vannucchi AM","year":"2013","unstructured":"Vannucchi AM , KantarjianH, KiladjianJ-Jet al. A pooled overall survival analysis of the COMFORT Studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Blood122(21), 2820 (2013).","journal-title":"Blood"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544411"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-81"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.177.177"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13379"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.5"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28441"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2844.2844"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2841.2841"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.5067.5067"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.1747.1747"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.789507"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.1591.1591"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.255"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11303"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23637"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S53348"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4057.4057"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.296"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302135"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.235"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1604"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.104"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.035"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-204950"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0518"},{"key":"e_1_3_2_93_1","unstructured":"Novartis Pharmaceuticals Canada Inc\n. Pr JAKAVI (ruxolitinib tablets) [Product Monograph]. www.novartis.ca\/asknovartispharma\/resources.htm?letter=J."},{"key":"e_1_3_2_94_1","unstructured":"Novartis Pharma Ag\n. JAKAVI Product Website. www.jakavi.com\/index.jsp."},{"key":"e_1_3_2_95_1","unstructured":"European Medicines Agency\n. Jakavi (ruxolitinib) [product information]. www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002464\/human_med_001568.jsp&mid=WC0b01ac058001d124."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.14.272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:00Z","timestamp":1719125100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.14.272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.2217\/fon.14.272"],"URL":"https:\/\/doi.org\/10.2217\/fon.14.272","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}